Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROMETHORPHAN POLISTIREX vs AMBENYL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextromethorphan polistirex is an NMDA receptor antagonist and sigma-1 receptor agonist. It inhibits serotonin reuptake and acts on the brain stem cough center to elevate the threshold for coughing.
AMBENYL is a combination product containing codeine (opioid agonist) and bromodiphenhydramine (antihistamine). Codeine binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception; bromodiphenhydramine antagonizes histamine H1 receptors, producing antitussive and sedative effects.
Symptomatic relief of nonproductive cough associated with upper respiratory tract infections,Off-label: Management of pseudobulbar affect (with quinidine),Off-label: Treatment of neuropathic pain
Cough suppression,Symptomatic relief of cough associated with colds or allergies
30-60 mg orally every 12 hours; not to exceed 120 mg in 24 hours.
Each 5 m L contains codeine phosphate 10 mg and diphenhydramine hydrochloride 12.5 mg. Adults: 10 m L (2 teaspoonfuls) orally every 4-6 hours as needed; maximum 40 m L per day.
Terminal half-life: 13–19 hours; clinical context: extended-release formulation due to polistirex complex; time to steady-state: ~3 days
Codeine: 2.5-3.5 h (terminal) with CYP2D6 poor metabolizers up to 6 h. Guaifenesin: 1-2 h.
Hepatic via CYP2D6 (O-demethylation to dextrorphan, active metabolite). Also undergoes N-demethylation via CYP3A4. Polymorphic metabolism (poor metabolizers at risk of toxicity).
Codeine is metabolized via CYP2D6 to morphine (active), CYP3A4 to norcodeine, and to a lesser extent via glucuronidation; bromodiphenhydramine is metabolized via CYP450 enzymes, primarily CYP2D6.
Renal: ~45% as unchanged drug and metabolites (dextrorphan conjugates); fecal: <2%; biliary: minimal
Renal: 60% unchanged codeine, 20% codeine-6-glucuronide; biliary/fecal: 20% as metabolites. Guaifenesin: renal 95% as unchanged drug and metabolites.
~50% bound; primarily to albumin
Codeine: 7-25% (albumin). Guaifenesin: negligible.
Vd: ~5–6 L/kg; clinical meaning: extensive tissue distribution, including CNS
Codeine: 3-6 L/kg (extensive tissue distribution). Guaifenesin: 1-2 L/kg.
Oral (polistirex): approximately 50–60% (first-pass metabolism reduces systemic availability)
Codeine: oral 90% (first-pass metabolism). Guaifenesin: oral 100% (well absorbed).
No specific dosing adjustment provided for dextromethorphan polistirex; use with caution in severe renal impairment (Cr Cl < 30 m L/min) due to potential accumulation of metabolites.
GFR 30-50 m L/min: use with caution, reduce dose by 25-50% and monitor for CNS depression. GFR <30 m L/min: avoid use or use with extreme caution; codeine accumulation risk.
No specific dosing adjustment provided; use with caution in severe hepatic impairment (Child-Pugh class C) due to reduced clearance.
Child-Pugh A: no adjustment needed. Child-Pugh B: use with caution, consider 50% dose reduction. Child-Pugh C: avoid use.
Children 6-12 years: 15-30 mg orally every 12 hours; not to exceed 60 mg in 24 hours. Children 2-5 years: 7.5-15 mg orally every 12 hours; not to exceed 30 mg in 24 hours. Not recommended under 2 years.
Not recommended for children under 6 years. Children 6-12 years: 5 m L (1 teaspoonful) orally every 4-6 hours; maximum 20 m L per day. Children >12 years: adult dosing.
Elderly patients may be more sensitive to anticholinergic effects; use the lowest effective dose and monitor for adverse effects such as sedation and dizziness.
Initiate at 5 m L every 6 hours due to increased sensitivity to anticholinergic and CNS depressant effects; monitor for confusion, sedation, and urinary retention.
No FDA black box warning.
Risk of respiratory depression, especially in children; risk of opioid addiction, abuse, and misuse; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; CYP2D6 ultra-rapid metabolizers may convert codeine to morphine at higher rates, leading to fatal respiratory depression.
Do not use with MAOIs or within 14 days of stopping MAOIs,Risk of serotonin syndrome when used with serotonergic drugs,Caution in patients with G6PD deficiency, hepatic impairment, or chronic cough associated with smoking, asthma, or emphysema,QT prolongation risk at supratherapeutic doses,Misuse potential with high doses causing dissociative effects
Respiratory depression; use in children <12 years contraindicated; risk of opioid-induced hyperalgesia; central nervous system depression; sedation; constipation; urinary retention; hypotension; anticholinergic effects; potential for misuse, abuse, and addiction; serotonin syndrome if used with other serotonergic drugs; adrenal insufficiency; risk of severe hypotension in volume-depleted patients; interactions with CNS depressants.
Concurrent use or within 14 days of MAOIs,Hypersensitivity to dextromethorphan or any component,Use in children under 2 years of age (OTC products)
Children <12 years; post-operative management in children <18 years after tonsillectomy/adenoidectomy; respiratory depression; acute or severe bronchial asthma; known hypersensitivity to codeine, bromodiphenhydramine, or any component; concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days; gastrointestinal obstruction; paralytic ileus.
Avoid grapefruit and grapefruit juice as they may alter metabolism. Take with or without food; food does not significantly affect absorption.
Zolpidem absorption is delayed and reduced when taken with food, especially high-fat meals. To achieve rapid onset of sleep, take on an empty stomach. Avoid grapefruit juice as it may increase zolpidem levels.
No well-controlled studies in pregnant women. Animal studies have not shown evidence of fetal harm. Based on limited human data, risk of major congenital malformations is low. Avoid use in first trimester due to theoretical risk based on weak NMDA antagonism.
FDA Pregnancy Category C. First trimester: Limited data; potential for fetal malformations (cleft palate, cardiac defects) based on animal studies with high-dose antihistamines. Second and third trimesters: Risk of neonatal respiratory depression, irritability, and withdrawal if used near term. Avoid in third trimester due to risk of premature closure of ductus arteriosus (codeine component).
Limited data; excreted in human breast milk in low amounts (M/P ratio not established). Theoretical risk of CNS depression in infant. Use with caution, especially in neonates or preterm infants. Consider immediate-release formulations if necessary.
Codeine is excreted in breast milk (M/P ratio ~2.5); risk of neonatal opioid toxicity (CNS depression). Diphenhydramine may inhibit lactation and cause drowsiness in infant. Contraindicated during breastfeeding due to possible severe adverse reactions in neonates.
No specific dose adjustments recommended for pregnancy; however, use lowest effective dose due to altered pharmacokinetics (increased volume of distribution, decreased plasma protein binding) potentially leading to reduced peak concentrations but unchanged half-life.
No established safe dose during pregnancy; avoid use. If unavoidable, use lowest effective dose for shortest duration. Pharmacokinetic changes (increased clearance, volume of distribution) may require dose adjustment, but due to risks, alternative therapy is recommended.
Dextromethorphan polistirex is an extended-release formulation allowing twice-daily dosing. Its antitussive effect lasts up to 12 hours. Caution in patients with asthma or COPD as it may reduce mucociliary clearance. Avoid concurrent use with MAOIs due to risk of serotonin syndrome. Not effective for chronic cough and should not be used for more than 7 days.
Ambien (zolpidem) is a non-benzodiazepine sedative-hypnotic used primarily for short-term insomnia. Avoid co-administration with alcohol or other CNS depressants. Use the lowest effective dose, especially in elderly patients, due to increased risk of falls and cognitive impairment. Monitor for complex sleep behaviors (e.g., sleep-driving). Tablet should be taken immediately before bedtime, not with or after a meal to avoid delayed onset.
Do not crush or chew the extended-release capsules or suspension; swallow whole or shake suspension well before use.,Do not exceed recommended doses; may cause drowsiness, avoid driving or operating machinery.,Discontinue use and consult healthcare provider if cough persists more than 7 days or is accompanied by fever, rash, or headache.,Avoid alcohol and other CNS depressants as they may increase sedation.,Inform healthcare provider if you are taking MAOIs (e.g., for depression, Parkinson's) or SSRIs to avoid serotonin syndrome.,Keep out of reach of children; overdose can be fatal.
Take zolpidem exactly as prescribed, only when you have at least 7-8 hours to devote to sleep.,Do not take zolpidem with alcohol or other sedatives as this can cause severe drowsiness and dangerous side effects.,Avoid driving or operating machinery the morning after taking zolpidem, as it may cause drowsiness, dizziness, or impaired coordination.,Report any unusual behaviors during sleep, such as walking, eating, or driving, to your doctor immediately.,Do not crush, chew, or split the extended-release tablets; swallow them whole.
"The combination of dextromethorphan, a centrally acting antitussive with NMDA receptor antagonist and sigma-1 receptor agonist properties, and aceprometazine, a phenothiazine neuroleptic with strong antihistaminergic and moderate anticholinergic and antidopaminergic effects, can result in additive central nervous system depression. This interaction may lead to excessive sedation, respiratory depression, impaired psychomotor function, and an increased risk of falls or cognitive impairment, particularly in elderly or debilitated patients. Concurrent use may also lower the seizure threshold, especially in patients with predisposing factors."
"Dextromethorphan, a serotonergic agent metabolized by CYP2D6, when combined with cariprazine, a dopamine D3/D2 receptor partial agonist, may increase the risk of serotonin syndrome due to additive serotonergic effects. Cariprazine can inhibit CYP2D6, reducing dextromethorphan clearance and elevating its plasma concentration, leading to enhanced serotonin activity. Clinically, patients may present with altered mental status, autonomic instability, and neuromuscular abnormalities."
"Dextromethorphan inhibits CYP2B6 and CYP2C9, which are involved in valproic acid metabolism. This results in decreased valproic acid clearance, potentially elevating valproic acid serum concentrations and increasing the risk of dose-dependent adverse effects such as hepatotoxicity, thrombocytopenia, and sedation. Concurrent use requires dose adjustment and close monitoring for signs of valproate toxicity."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROMETHORPHAN POLISTIREX vs AMBENYL, answered by our medical review team.
DEXTROMETHORPHAN POLISTIREX is a Antitussive that works by Dextromethorphan polistirex is an NMDA receptor antagonist and sigma-1 receptor agonist. It inhibits serotonin reuptake and acts on the brain stem cough center to elevate the threshold for coughing.. AMBENYL is a Antitussive/Antihistamine Combination that works by AMBENYL is a combination product containing codeine (opioid agonist) and bromodiphenhydramine (antihistamine). Codeine binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception; bromodiphenhydramine antagonizes histamine H1 receptors, producing antitussive and sedative effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROMETHORPHAN POLISTIREX and AMBENYL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROMETHORPHAN POLISTIREX is: 30-60 mg orally every 12 hours; not to exceed 120 mg in 24 hours.. The standard adult dose of AMBENYL is: Each 5 m L contains codeine phosphate 10 mg and diphenhydramine hydrochloride 12.5 mg. Adults: 10 m L (2 teaspoonfuls) orally every 4-6 hours as needed; maximum 40 m L per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DEXTROMETHORPHAN POLISTIREX and AMBENYL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DEXTROMETHORPHAN POLISTIREX is classified as Category C. No well-controlled studies in pregnant women. Animal studies have not shown evidence of fetal harm. Based on limited human data, risk of major congenital malformations is low. Avoi. AMBENYL is classified as Category C. FDA Pregnancy Category C. First trimester: Limited data; potential for fetal malformations (cleft palate, cardiac defects) based on animal studies with high-dose antihistamines. Se. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.